You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PARP inhibitors

Showing 1 - 25 of 4,433
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy Trial in Rotterdam (olaparib)

Recruiting
  • Neuroendocrine Tumors
  • Peptide Receptor Radionuclide Therapy
  • Rotterdam, South Holland, Netherlands
    Erasmus MC
May 19, 2023

Ovarian Cancer Patients Receiving Maintenance PARP Inhibitors

Recruiting
  • Ovarian Carcinoma
  • Biospecimen Collection
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 5, 2023

Ovarian Cancer Trial in Madrid (Exercise and dietary recommendations)

Not yet recruiting
  • Ovarian Cancer
  • Exercise and dietary recommendations
  • Madrid, Spain
  • +3 more
Nov 15, 2023

HRD Cancer, SCLC, Advanced Solid Tumors Trial run by the NCI (Berzosertib, Sacituzumab Govitecan)

Recruiting
  • HRD Cancer
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Epithelial Ovarian Cancer Eligible to PARP Inhibitors

Recruiting
  • Ovarian Cancer
  • blood sample
  • Besançon, France
  • +1 more
Mar 24, 2022

Effect of PARP Inhibitors on Glomerular Filtration Rate

Terminated
  • Solid Tumor
  • +2 more
  • Kidney Function Test
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Jan 20, 2022

Ovarian Cancer, Ovarian Carcinoma, Platinum-resistant Ovarian Cancer Trial (Pamiparib, Surufatinib)

Not yet recruiting
  • Ovarian Cancer
  • +4 more
  • (no location specified)
Aug 8, 2022

Breast Cancer After Ovarian Cancer During and/or After Therapy:

Recruiting
  • BRCA-Associated Breast Carcinoma
  • Next-generation sequencing (NGS) assay TruSight Oncology 500 (TSO 500).
  • Rome, RM, Italy
    Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Mar 9, 2023

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

Completed
  • Cancer
  • PARP inhibitor
  • Caen, Basse Normandie, France
    Alexandre Joachim
Sep 16, 2021

Metastatic Castration-resistant Prostate Cancer Trial in Guangzhou

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    Nov 1, 2021

    PARP Inhibitors Use in Patients With Ovarian Cancer

    Active, not recruiting
    • Ovarian Cancer
    • PARP inhibitor
    • Athens, Attiki, Greece
      Adamantia Nikolaidi
    Jul 30, 2021

    Ovarian Cancer Trial in Villejuif (AsiDNA, Niraparib, Olaparib)

    Recruiting
    • Ovarian Cancer
    • Villejuif, Val De Marne, France
      Gustave Roussy
    Sep 27, 2021

    Pulmonary Toxicities Related to PARP Inhibitors (PulmonaRIB)

    Recruiting
    • Cancer
    • olaparib, rucaparib, niraparib, talazoparib, veliparib, pamiparib
    • Caen, Basse Normandie, France
      Alexandre Joachim
    May 27, 2021

    Myelodysplastic Syndrome and Acute Myeloid Leukemia Related to

    Completed
    • Cancer
    • PARP Inhibitors
    • Caen, Basse Normandie, France
      Alexandre Joachim
    Mar 9, 2021

    HRD and Resistance to PAPPi in EOC Patients

    Recruiting
    • Epithelial Ovarian Cancer
    • +6 more
    • Testing of homologous recombination deficiency
    • Beijing, Beijing, China
      Lei Li
    Mar 26, 2022

    PARP Inhibitors-related Efficacy in Ovarian Cancer

    Recruiting
    • Ovarian Cancer
    • +2 more
    • PARP inhibitors
    • Nanjing, Jiangsu, China
      Xiaoxiang Chen, MD,PhD
    Jan 17, 2021

    Small Cell Lung Cancer Trial (Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors)

    Not yet recruiting
    • Small Cell Lung Cancer
    • Camrelizumab Anti-PD-1 antibody Fluzoparib PARP inhibitors
    • (no location specified)
    Mar 1, 2021

    Homologous Recombination Deficiency in Chinese Ovarian Cancer

    Not yet recruiting
    • Ovarian Cancer
    • +2 more
    • PARP inhibitor
    • Nanjing, Jiangsu, China
      Xiaoxiang Chen, MD,PhD
    Sep 4, 2021

    Finisterian Patients Treated With PARP Inhibitors for Ovarian

    Completed
    • Ovarian Neoplasm
      • Brest, France
      • +3 more
      Sep 28, 2020

      Ovarian Cancer, Ovarian and Fallopian Tube Cysts and Tumors, Tumors by Site Trial in Nanjing (Anlotinib, Olaparib)

      Recruiting
      • Ovarian Cancer
      • +18 more
      • Nanjing, Jangsu, China
        JiangSu Cancer Hospital
      Oct 29, 2020

      Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone Trial in Shanghai (Camrelizumab and fluzoparib with concurrent stereotactic body

      Recruiting
      • Sarcoma
      • +2 more
      • Camrelizumab and fluzoparib with concurrent stereotactic body radiotherapy (SBRT)
      • Shanghai, Shanghai, China
        Ruijin Hospital, Shanghai Jiao Tong University, School of Medici
      Oct 3, 2023

      Breast Cancer Trial in Boston (Talazoparib, Sacituzumab Govitecan)

      Recruiting
      • Breast Cancer
      • Boston, Massachusetts
      • +1 more
      Jan 6, 2023

      Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma

      Not yet recruiting
      • Anatomic Stage III Breast Cancer AJCC v8
      • +3 more
      • (no location specified)
      Jul 28, 2023

      Predictive Immune Biomarkers of Response to PAPR Inhibitors

      Recruiting
      • Ovarian Cancer
        • Seoul, Korea, Republic of
          Yonsei University Health System, Severance Hospital
        Nov 25, 2022

        Melanoma Trial (Fluzoparib Camrelizumab Temozolomide)

        Not yet recruiting
        • Melanoma
        • Fluzoparib Camrelizumab Temozolomide
        • (no location specified)
        Aug 9, 2023